Emulate key facts
as of Oct 2026- Developer of organ-on-a-chip technology designed to predict human response with greater precision and detail than other experimental testing methods.
- Emulate is valued at approximately $140.0M as of Oct 2026, set at its later-stage round, Mar 2024; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $278.4M across 7 recorded rounds; the latest was Later Stage VC ($57.5M) in Aug 2021.
- Notable investors include Alumni Ventures, Founders Fund, United States Department of War, Qiming Venture Partners, CSC UpShot Ventures — 33 tracked in total.
- Emulate has filed 7 Form Ds with the SEC since 2014, most recently Sep 2021 ($57.5M sold to 7 investors).
- Status: Privately Held (backing).
Valued at $140.0M at its later-stage round, Mar 2024. Nothing has traded since.
- ·The complete investor list: 33 names
- ·Watch Emulate: the Monday email on marks, rounds and moves
Emulate funding rounds
7 roundsWho backs Emulate
33+Emulate valuation
Emulate was valued at $140 million at its later-stage round in Mar 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Emulate raised?
Emulate has raised $278 million across 7 recorded rounds since 2014. The largest was a $745,750 seed round in Oct 2017; the most recent was a $57.5 million later-stage round in Aug 2021.
Emulate has filed 7 Form Ds with the SEC since 2014, most recently in Sep 2021 ($57.5 million sold to 7 investors).
Emulate investors
33 investors are on record for Emulate, including Alumni Ventures, Founders Fund, United States Department of War and Qiming Venture Partners. By type, the record holds 8 venture capital firms and 1 family office. The later-stage round in Aug 2021 drew 7 investors.
About Emulate
Developer of organ-on-a-chip technology designed to predict human response with greater precision and detail than other experimental testing methods. The company's human emulation system provides a window into the inner workings of human biology and disease, offering researchers an innovative technology that conventional cell culture or animal-based experimental testing, enabling doctors to get detailed insights into the human body and its cells.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2013
- Employees
- 76
- Website
- emulatebio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.